Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05985161
- Locations
- 🇺🇸
Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta (Data Collection and Specimen Analysis), Atlanta, Georgia, United States
🇺🇸Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts, United States
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 40
- Registration Number
- NCT05983276
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT05954780
- Locations
- 🇩🇪
Gemeinschaftspraxis für Hämatologie und Onkologie GbR, Ravensburg, Baden-Württemberg, Germany
🇦🇹Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Wien, Austria
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 42
- Registration Number
- NCT05951855
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- St. Jude Children's Research Hospital
- Registration Number
- NCT05952687
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 35
- Registration Number
- NCT05900882
- Locations
- 🇨🇳
Nanjing First People's Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Taizhou People's Hospital, Taizhou, Jiangsu, China
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05852028
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, China
🇨🇳Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, China
An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 20
- Registration Number
- NCT05822050
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT05820763
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT05805072
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.